Two studies just published in CID review the limitations of the current indication to only prescribe injectable CAB/RPV-LA to people who have undetectable viral load on oral ART.
The first is a retrospective review of people with complex HIV histories at a single centre in the US, which has reported high response rates from injectable ART, despite switching when viral load was still detectable >50 copies/mL. The second is a modelling study that provocatively challenges the current recommendations as a denial of access and reports significant benefits from broader access.
These results are timely as two studies at IAS 2025 presented results on similar off-label prescribing of CAB/RPV-LA.
Read the full news story at HIV i-Base.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.